TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
Active, not recruiting · NCT05862324 · Registry updated 2025-02-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2025-02-14 | NCT05862324 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Triumvira Immunologics, Inc. | 1 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Hospitalier de l'Université de Montréal | Montreal | Canada | 13 |
| Cincinnati Cancer Center | Cincinnati | United States | 1 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Princess Margaret Cancer Center | Toronto | Canada | 2 |
| University of California San Diego | San Diego | United States | 20 |
| University of Miami Sylvester Comprehensive Cancer Center | Miami | United States | 18 |
| University of Southern California | Los Angeles | United States | 110 |